Hyperoside (Compound)

Synonyms:Hyperoside, 482-36-0, Hyperin, Hyperosid, Quercetin 3-galactoside, Hyperozide, Quercetin-3-O-galactoside, Quercetin-3-galactoside, Hyperasid, Jyperin, Quercetin 3-O-beta-D-galactopyranoside, Quercetin 3-D-galactoside, UNII-8O1CR18L82, QUERCETIN 3-B-D-GALACTOSIDE, Quercetin 3-beta-D-galactopyranoside, MFCD00016933, quercetin 3-O-galactoside, NSC 407304, CHEMBL251254, 2-(3,4-dihydroxyphenyl)-5,7-dihydroxy-3-[(2S,3R,4S,5R,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxychromen-4-one, CHEBI:67486, 8O1CR18L82, 2-(3,4-Dihydroxyphenyl)-3-(beta-D-galactopyranosyloxy)-5,7-dihydroxy-4H-1-benzopyran-4-one, 2-(3,4-dihydroxyphenyl)-5,7-dihydroxy-3-(((2S,3R,4S,5R,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)tetrahydro-2H-pyran-2-yl)oxy)-4H-chromen-4-one, 4H-1-Benzopyran-4-one, 2-(3,4-dihydroxyphenyl)-3-(.beta.-D-galactopyranosyloxy)-5,7-dihydroxy-, quercetin galactoside, CCRIS 9339, p Hyperin, quercetin 3-O-beta-D-glucopyranoside, Quercetin 3-.beta.-D-galactopyranoside, Quercetin 3-O-.beta.-D-galactopyranoside, Hyperin,(S), EINECS 207-580-6, Hyperin (8CI), BIDD:PXR0057, MLS000759538, 2-yloxy)-4H-chromen-4-one, jm5b01461, Compound 84, MEGxp0_000392, SCHEMBL1250514, ACon1_000623, Quercetin 3-O-beta-D-galactoside, BDBM429266, HMS2051H17, HY-N0452, quercetin 3-O--D-galactopyranoside, ZINC3973253, BDBM50241367, s5453, AKOS015896780, 6-(hydroxymethyl)tetrahydro-2H-pyran-, CCG-100970, MCULE-5363142212, NC00220, NCGC00168902-03, 2-(3,4-dihydroxyphenyl)-5,7-dihydroxy-3-[(2S,3R,4S,5R,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)tetrahydropyran-2-yl]oxy-chromen-4-one, AS-56199, S600, SMR000466394, 2-(3,4-dihydroxyphenyl)-5,7-dihydroxy-, CS-0008982, N1838, Quercetin 3-D-galactoside, >=97.0% (HPLC), AB00639910-03, 3-((2S,3R,4S,5R,6R)-3,4,5-trihydroxy-, 482H360, 3,3',4',5,7-Pentahydroxyflavone 3-D-galactoside, Hyperoside, primary pharmaceutical reference standard, Q-100530, Q5242815, BRD-K84955386-001-01-1, 3-O-b-D-Galactopyranosyloxy-3',4',5,7-tetrahydroxyflavone, Hyperoside, United States Pharmacopeia (USP) Reference Standard, 2-(3,4-dihydroxyphenyl)-5,7-dihydroxy-4-oxo-4H-chromen-3-yl beta-D-galactopyranoside, 2-(3,4-Dihydroxyphenyl)-5,7-dihydroxy-4-oxo-4H-chromen-3-yl hexopyranoside #, 2-(3,4-Dihydroxy-phenyl)-5,7-dihydroxy-3-((2S,4R,5R)-3,4,5-trihydroxy-6-hydroxymethyl-tetrahydro-pyran-2-yloxy)-chromen-4-one, 2-(3,4-dihydroxyphenyl)-5,7-dihydroxy-3-((2S,3R,4S,5R,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)tetrahydro-2H-pyran-2-yloxy)-4H-chromen-4-one, 2-(3,4-dihydroxyphenyl)-5,7-dihydroxy-3-{[(2S,3R,4S,5R,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}-4H-chromen-4-one, 4H-1-Benzopyran-4-one, 2-(3,4-dihydroxyphenyl)-3-(beta-D-galactopyranosyloxy)-5,7-dihydroxy-
Pubchem:PUBCHEM:5281643
Id:5281643
Description:nan

Analyze

Data Distillery
CFDE DD-Knowledge Graph

The CFDE Data Distillery Knowledge Graph contains entities and relationships across the CFDE. View Hyperoside's neighborhood in the knowledge graph.

Gene and Drug Landing Page Aggegrator
GDLPA Landing Pages Links

The Gene and Drug Landing Page Aggregator (GDLPA) finds links to primary and secondary source information from CFDE and other resources. Discover landing pages for Hyperoside.

Playbook Workflow Builder
Playbook Workflow Builder

The Playbook Workflow Builder helps you interactively construct workflows leveraging CFDE APIs without code. Start a new workflow with Hyperoside.

Results found

Linked to

DISPLAY PER PAGE
This repository is under review for potential modification in compliance with Administration directives.